109,554 Shares in Xencor, Inc. $XNCR Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP acquired a new position in Xencor, Inc. (NASDAQ:XNCR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 109,554 shares of the biopharmaceutical company’s stock, valued at approximately $1,677,000. Xencor accounts for about 1.3% of Seven Fleet Capital Management LP’s portfolio, making the stock its 11th largest position.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in XNCR. ProShare Advisors LLC increased its stake in shares of Xencor by 6.5% during the 4th quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 1,026 shares during the last quarter. Cerity Partners LLC lifted its holdings in Xencor by 3.8% during the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 1,143 shares during the last quarter. State of Tennessee Department of Treasury lifted its stake in shares of Xencor by 6.2% during the 2nd quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 1,784 shares in the last quarter. Diversified Trust Co. boosted its holdings in shares of Xencor by 13.8% in the fourth quarter. Diversified Trust Co. now owns 18,442 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 2,242 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Xencor by 3.3% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock worth $550,000 after purchasing an additional 2,256 shares during the period.

Xencor Stock Down 1.1%

Shares of NASDAQ:XNCR opened at $12.64 on Friday. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69. The company’s fifty day moving average is $12.11 and its 200 day moving average is $12.95. The stock has a market cap of $937.13 million, a PE ratio of -5.52 and a beta of 0.92.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $27.86 million. During the same period in the previous year, the company earned ($0.66) EPS. The company’s quarterly revenue was down 86.2% on a year-over-year basis. Sell-side analysts anticipate that Xencor, Inc. will post -3.84 EPS for the current year.

Analyst Ratings Changes

XNCR has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Zacks Research lowered Xencor from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Finally, Barclays boosted their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Xencor currently has an average rating of “Hold” and a consensus target price of $24.50.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.